Avsnitt
-
This episode delivers a rigorous evaluation of hemoglobin A1c pitfalls where the marker fails to accurately reflect true glycemia. We examine how altered erythrocyte turnover, hemoglobin variants, and specific clinical conditions distort glycation dynamics independently of plasma glucose levels. Listeners will learn to identify when to suspect inaccurate A1c readings, how conditions like advanced chronic kidney disease or hemoglobinopathies confound data, and when to utilize alternative biomarkers like fructosamine or continuous glucose monitoring metrics instead.
-
This episode delivers a definitive analysis of cystic fibrosis-related diabetes, the most common extra-pulmonary complication of cystic fibrosis. We explore its unique mixed pathophysiology, combining primary insulin insufficiency from progressive pancreatic fibrosis with fluctuating insulin resistance driven by chronic pulmonary inflammation. Listeners will learn to identify the clinical impact on nutritional status and lung function, understand why oral glucose tolerance tests are required for screening, and see why insulin remains the primary therapeutic intervention.
-
Saknas det avsnitt?
-
This episode delivers a clinical breakdown of HNF1B-MODY, also known as MODY5, which is characterized by heterozygous mutations in the hepatocyte nuclear factor-1-beta gene. We examine its systemic presentation, highlighting that renal cysts and diabetes syndrome frequently precede carbohydrate intolerance. Listeners will learn to identify structural renal anomalies, genital tract abnormalities, and pancreatic exocrine insufficiency, while understanding why these patients experience early progressive renal failure and require early insulin therapy due to a profound hepatic insulin resistance.
-
This episode delivers a precise analysis of GCK-MODY, also known as MODY2, a genetic form of diabetes caused by heterozygous inactivating mutations in the glucokinase gene. We explore how this molecular defect alters the pancreatic glucose sensor, shifting the glycemic threshold upward. Listeners will learn why patients exhibit lifelong, stable, mild fasting hyperglycemia that rarely progresses, why microvascular complications are exceptionally uncommon, and why pharmacological management is typically unnecessary outside of pregnancy.
-
This episode of Endocrine Deep Dives explores HNF4A MODY, also known as MODY 1, a rare form of monogenic diabetes caused by mutations in the hepatocyte nuclear factor 4 alpha gene. We break down its distinct clinical phenotype, including macrosomia and neonatal hypoglycemia at birth, followed by progressive beta cell dysfunction later in life. We also discuss diagnostic screening criteria and why these patients show exquisite sensitivity to low dose sulfonylureas.
-
This episode of Endocrine Deep Dives explores HNF1A MODY, or MODY 3, the most common form of monogenic diabetes. We examine its characteristic clinical presentation, marked by progressive beta cell dysfunction, a low renal threshold for glucose, and a lack of pancreatic autoantibodies. We discuss the importance of genetic testing to differentiate it from type 1 and type 2 diabetes and outline why low dose sulfonylureas are the preferred first line pharmacological treatment.
-
This episode breaks down postmenopausal ovarian hyperthecosis, a benign but impactful condition where altered ovarian cells overproduce androgens. We explore how postmenopausal hormonal shifts and insulin resistance synergize to drive severe virilization, hirsutism, and heightened metabolic or endometrial risks. Learn to differentiate this slow-progressing disorder from aggressive ovarian tumors using precise diagnostic imaging and lab panels. Finally, we review management strategies, from definitive surgical oophorectomy to targeted medical therapies and metabolic interventions.
-
This episode explores the biological mechanisms and medical management of infertility in polycystic ovary syndrome, focusing on how hormonal imbalances and insulin resistance cause follicular arrest. We evaluate pharmacological interventions, highlighting why letrozole has surpassed clomiphene citrate as the premier first-line agent for ovulation induction. The discussion covers adjunctive therapies like metformin, surgical options including ovarian drilling, and optimized advanced reproductive technology protocols designed to minimize ovarian hyperstimulation syndrome risk during in vitro fertilization.
-
In this episode, we unpack premature ovarian insufficiency, exploring why normal ovarian function ceases before age forty. We break down the clinical diagnostic criteria, specifically tracking elevated follicle-stimulating hormone levels and menstrual irregularities. From genetic factors like Turner syndrome to autoimmune and iatrogenic causes, we map out the underlying etiologies. Finally, we discuss the systemic long-term health risks of early estrogen loss, such as osteoporosis, and review hormone replacement therapy strategies to safeguard patient health.
-
In this episode, we dive deep into diminished ovarian reserve, exploring why a premature drop in a woman's egg supply disrupts fertility. We break down the underlying shift in ovarian biology, including how falling anti-mullerian hormone and inhibin-B levels signal the brain to pump out more follicle-stimulating hormone. You will learn about the cellular changes affecting egg quality, the main diagnostic tools clinicians use like antral follicle counts, and how this condition differs from total ovarian failure.
-
In this episode we break down the pathophysiology and management of menopausal vasomotor symptoms, exploring the hypothalamic dysfunction driving hot flashes. We review primary hormone therapy guidelines, emphasizing individualized low-dose strategies. For patients seeking nonhormonal alternatives, we analyze the clinical roles of gabapentin, SSRIs, and novel neurokinin receptor antagonists like fezolinetant and elinzanetant. Finally, we discuss racial variations in symptom duration and how to implement shared decision-making to balance immediate relief with long-term patient safety.
-
In this episode we unpack the intricate biochemistry of ovarian steroidogenesis, focusing on the cooperative two-cell two-gonadotropin architecture between theca and granulosa cells. We trace cellular pathways from cholesterol transport via STAR to estrogen synthesis by aromatase. The discussion explores cyclic hormonal shifts during the follicular and luteal phases.
-
This episode provides a deep clinical breakdown of human folliculogenesis, tracing the 375-day trajectory from primordial activation to dominant follicle selection. We explore the transition from gonadotropin-independent paracrine pathways to the endocrine-driven two-cell, two-gonadotropin model. The discussion connects these cellular mechanisms directly to clinical practice, analyzing the pathophysiology of primary ovarian insufficiency, the follicular arrest seen in polycystic ovary syndrome, and the protocols used to override mono-ovulation during controlled ovarian hyperstimulation.
-
This episode breaks down the complex etiology and diagnostic pitfalls of hyperprolactinemia, shifting from normal physiologic responses like pregnancy to drug-induced elevations from antipsychotics and prokinetics. We analyze critical laboratory artifacts, detailing how the hook effect masks giant macroprolactinomas and how macroprolactinemia causes asymptomatic elevations. Finally, the discussion explores how to differentiate non-functioning macroadenomas from true prolactinomas, and examines the downstream effects of hypogonadotropic hypogonadism on fertility and metabolic bone disease.
-
This episode goes into the intricacies of osteoporosis coding.
https://share.jotbird.com/soft-steady-mesa-willow
-
In this episode, we dive into the Trabecular Bone Score, a groundbreaking imaging tool redefining how we assess skeletal health. While traditional bone density scans only measure mineral quantity, this technology evaluates the internal microarchitecture of the lumbar spine. We explore why many patients suffer fractures despite normal density scores, and how this tool bridges diagnostic gaps for individuals with diabetes or on glucocorticoids, ultimately offering a more precise look at true bone quality.
-
This episode is my take on understanding the basics or Medicare insurance. More episodes to come.
-
This episode breaks down the clinical management matrix for acromegaly, providing an advanced roadmap for endocrinologists managing growth hormone hypersecretion. We review transsphenoidal surgery guidelines, post-operative remission metrics, and tailored medical management algorithms. Discover how to strategically navigate first and second generation somatostatin receptor ligands, dopamine agonists, and growth hormone receptor antagonists. Finally, we dissect mandatory transition indicators, critical safety monitoring for drug-induced toxicities, and lifelong surveillance protocols for systemic comorbidities.
-
This episode explores the clinical progression, diagnosis, and long term management of acromegaly, a rare condition driven by chronic growth hormone excess. We trace the patient journey from early subtle metabolic shifts to irreversible skeletal changes and systemic organ damage caused by prolonged diagnostic delays. The discussion breaks down the essential diagnostic protocol including insulin like growth factor one screening, oral glucose tolerance testing, and pituitary magnetic resonance imaging. Finally, we highlight the vital role of multidisciplinary interventions to manage cardiovascular risks, sleep apnea, oncological monitoring, and persistent metabolic complications.
-
In this episode, we break down the complex pathophysiological and genetic landscape of acromegaly, looking beyond the simple diagnosis of growth hormone hypersecretion. We explore the critical cellular differences between densely and sparsely granulated somatotroph adenomas, detailing how their unique cytokeratin networks and somatostatin receptor profiles dictate treatment response. Finally, we examine the genetic drivers behind familial syndromes like Carney complex and X-linked acrogigantism, alongside the diagnostic challenges posed by rare ectopic tumors.
- Visa fler
